-
公开(公告)号：US09034849B2
公开(公告)日：2015-05-19
申请号：US13019262
申请日：2011-02-01
申请人： Brian C. Austad , Louis Grenier , Michael J. Grogan , Tao Liu , Ching Kam Lo , Theodore A. Martinot , Lin-Chen Yu
发明人： Brian C. Austad , Louis Grenier , Michael J. Grogan , Tao Liu , Ching Kam Lo , Theodore A. Martinot , Lin-Chen Yu
CPC分类号： C07F5/05 , C07B2200/13 , C07F5/025
摘要： The present invention provides fatty acid amide hydrolase inhibitors, solid forms thereof, compositions thereof, and methods of making and using the same.
摘要翻译： 本发明提供脂肪酸酰胺水解酶抑制剂，其固体形式，其组合物及其制备和使用方法。
-
公开(公告)号：US20110201574A1
公开(公告)日：2011-08-18
申请号：US13019262
申请日：2011-02-01
申请人： Brian C. AUSTAD , Louis Grenier , Michael J. Grogan , Tao Liu , Ching Kam Lo , Theodore A. Martinot , Lin-Chen Yu
发明人： Brian C. AUSTAD , Louis Grenier , Michael J. Grogan , Tao Liu , Ching Kam Lo , Theodore A. Martinot , Lin-Chen Yu
IPC分类号： A61K31/69 , C07F5/02 , C07F5/05 , A61P29/00 , A61P37/02 , A61P3/00 , A61P25/00 , A61P27/06 , A61P9/00 , A61P1/00 , A61P17/00
CPC分类号： C07F5/05 , C07B2200/13 , C07F5/025
摘要： The present invention provides fatty acid amide hydrolase inhibitors, solid forms thereof, compositions thereof, and methods of making and using the same.
摘要翻译： 本发明提供脂肪酸酰胺水解酶抑制剂，其固体形式，其组合物及其制备和使用方法。
-
公开(公告)号：US08329675B2
公开(公告)日：2012-12-11
申请号：US13049779
申请日：2011-03-16
申请人： Julian Adams , Mark L. Behnke , Alfredo C. Castro , Catherine A. Evans , Louis Grenier , Michael J. Grogan , Tao Liu , Daniel A. Snyder , Thomas T. Tibbitts
发明人： Julian Adams , Mark L. Behnke , Alfredo C. Castro , Catherine A. Evans , Louis Grenier , Michael J. Grogan , Tao Liu , Daniel A. Snyder , Thomas T. Tibbitts
摘要： The present invention provide compounds, and pharmaceutical compositions thereof, encompassed by the formulae (I), (II) or (III). The present invention also provides methods for treating an FAAH mediated disease, disorder or condition by administering a therapeutically effective amount of a provided compound of the formulae (I), (II) or (III), or a pharmaceutical composition thereof, to a patient in need thereof. Additionally, the present invention provides methods for inhibiting FAAH in a patient by administering a therapeutically effective amount of a compound of the formulae (I), (II) or (III), or a pharmaceutical composition thereof, to a patient in need thereof.
摘要翻译： 本发明提供由式（I），（II）或（III）包含的化合物及其药物组合物。 本发明还提供了通过向患者施用治疗有效量的所提供的式（I），（II）或（III）化合物或其药物组合物来治疗FAAH介导的疾病，病症或病症的方法。 需要它。 此外，本发明提供了通过向有需要的患者施用治疗有效量的式（I），（II）或（III）化合物或其药物组合物来抑制患者的FAAH的方法。
-
公开(公告)号：US20110224171A1
公开(公告)日：2011-09-15
申请号：US13049779
申请日：2011-03-16
申请人： Julian Adams , Mark L. Behnke , Alfredo C. Castro , Catherine A. Evans , Louis Grenier , Michael J. Grogan , Tao Liu , Daniel A. Snyder , Thomas T. Tibbitts
发明人： Julian Adams , Mark L. Behnke , Alfredo C. Castro , Catherine A. Evans , Louis Grenier , Michael J. Grogan , Tao Liu , Daniel A. Snyder , Thomas T. Tibbitts
IPC分类号： A61K31/69 , A61P29/00 , A61P37/00 , A61P25/24 , A61P25/02 , A61P25/00 , A61P27/06 , A61P9/00 , A61P25/06
摘要： The present invention provide compounds, and pharmaceutical compositions thereof, encompassed by the formulae (I), (II) or (III). The present invention also provides methods for treating an FAAH mediated disease, disorder or condition by administering a therapeutically effective amount of a provided compound of the formulae (I), (II) or (III), or a pharmaceutical composition thereof, to a patient in need thereof. Additionally, the present invention provides methods for inhibiting FAAH in a patient by administering a therapeutically effective amount of a compound of the formulae (I), (II) or (III), or a pharmaceutical composition thereof, to a patient in need thereof.
摘要翻译： 本发明提供由式（I），（II）或（III）包含的化合物及其药物组合物。 本发明还提供了通过向患者施用治疗有效量的所提供的式（I），（II）或（III）化合物或其药物组合物来治疗FAAH介导的疾病，病症或病症的方法。 需要它。 此外，本发明提供了通过向有需要的患者施用治疗有效量的式（I），（II）或（III）化合物或其药物组合物来抑制患者的FAAH的方法。
-
公开(公告)号：US20110034437A1
公开(公告)日：2011-02-10
申请号：US12782658
申请日：2010-05-18
申请人： Mark L. Behnke , Alfredo C. Castro , Lawrence K. Chan , Catherine A. Evans , Louis Grenier , Michael J. Grogan , Yves Leblanc , Tao Liu , Stephane Peluso , Daniel A. Snyder , Thomas T. Tibbitts
发明人： Mark L. Behnke , Alfredo C. Castro , Lawrence K. Chan , Catherine A. Evans , Louis Grenier , Michael J. Grogan , Yves Leblanc , Tao Liu , Stephane Peluso , Daniel A. Snyder , Thomas T. Tibbitts
IPC分类号： A61K31/55 , C07D261/20 , A61K31/42 , A61K31/438 , C07D498/10 , A61P25/00 , A61P3/00 , A61P9/00 , A61P1/08 , A61P25/28 , A61P25/30 , A61P25/20 , A61P3/04
CPC分类号： C07D498/10 , A61K31/42 , A61K31/438 , A61K31/55 , C07D261/20 , C07D498/04
摘要： The present invention provides isoxazoline FAAH inhibitors of the formula (I): or pharmaceutically acceptable forms thereof, wherein each of G, Ra, Rb, Rc, and Rd are as defined herein. The present invention also provides pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable form thereof, and a pharmaceutically acceptable excipient.The present invention also provides methods for treating an FAAH-mediated condition comprising administering a therapeutically effective amount of a compound of formula (I), or pharmaceutically acceptable form thereof, to a subject in need thereof.
-
公开(公告)号：US09149465B2
公开(公告)日：2015-10-06
申请号：US12782650
申请日：2010-05-18
申请人： Mark L. Behnke , Alfredo C. Castro , Lawrence K. Chan , Catherine A. Evans , Louis Grenier , Michael J. Grogan , Yves Leblanc , Tao Liu , Stephane Peluso , Daniel A. Snyder , Thomas T. Tibbitts
发明人： Mark L. Behnke , Alfredo C. Castro , Lawrence K. Chan , Catherine A. Evans , Louis Grenier , Michael J. Grogan , Yves Leblanc , Tao Liu , Stephane Peluso , Daniel A. Snyder , Thomas T. Tibbitts
IPC分类号： C07D261/04 , A61K31/5377 , A61K31/42 , A61K31/4245 , A61K31/4439 , A61K31/4709 , A61K31/501 , A61K31/506 , C07D413/04 , C07D413/12 , C07D413/14 , C07D471/04
CPC分类号： A61K31/42 , A61K31/4245 , A61K31/4439 , A61K31/4709 , A61K31/501 , A61K31/506 , A61K31/5377 , C07D261/04 , C07D413/04 , C07D413/12 , C07D413/14 , C07D471/04
摘要： The present invention provides isoxazoline FAAH inhibitors of the formula (I): or pharmaceutically acceptable forms thereof, wherein each of G, Ra, Rb, Rc, and Rd are as defined herein. The present invention also provides pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable form thereof, and a pharmaceutically acceptable excipient.The present invention also provides methods for treating an FAAH-mediated condition comprising administering a therapeutically effective amount of a compound of formula (I), or pharmaceutically acceptable form thereof, to a subject in need thereof.
摘要翻译： 本发明提供式（I）的异恶唑啉FAAH抑制剂或其药学上可接受的形式，其中G，Ra，Rb，Rc和Rd各自如本文所定义。 本发明还提供包含式（I）化合物或其药学上可接受的形式的药物组合物和药学上可接受的赋形剂。 本发明还提供了治疗FAAH介导的病症的方法，包括向有需要的受试者施用治疗有效量的式（I）化合物或其药学上可接受的形式。
-
公开(公告)号：US08765735B2
公开(公告)日：2014-07-01
申请号：US12782658
申请日：2010-05-18
申请人： Mark L. Behnke , Alfredo C. Castro , Lawrence K. Chan , Catherine A. Evans , Louis Grenier , Michael J. Grogan , Yves Leblanc , Tao Liu , Stephane Peluso , Daniel A. Snyder , Thomas T. Tibbitts
发明人： Mark L. Behnke , Alfredo C. Castro , Lawrence K. Chan , Catherine A. Evans , Louis Grenier , Michael J. Grogan , Yves Leblanc , Tao Liu , Stephane Peluso , Daniel A. Snyder , Thomas T. Tibbitts
IPC分类号： A01N43/00 , A61K31/55 , A01N43/42 , A61K31/44 , A01N43/80 , A61K31/42 , C07D261/02 , C07D401/00
CPC分类号： C07D498/10 , A61K31/42 , A61K31/438 , A61K31/55 , C07D261/20 , C07D498/04
摘要： The present invention provides isoxazoline FAAH inhibitors of the formula (I): or pharmaceutically acceptable forms thereof, wherein each of G, Ra, Rb, Rc, and Rd are as defined herein. The present invention also provides pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable form thereof, and a pharmaceutically acceptable excipient.The present invention also provides methods for treating an FAAH-mediated condition comprising administering a therapeutically effective amount of a compound of formula (I), or pharmaceutically acceptable form thereof, to a subject in need thereof.
摘要翻译： 本发明提供式（I）的异恶唑啉FAAH抑制剂或其药学上可接受的形式，其中G，Ra，Rb，Rc和Rd各自如本文所定义。 本发明还提供包含式（I）化合物或其药学上可接受的形式的药物组合物和药学上可接受的赋形剂。 本发明还提供了治疗FAAH介导的病症的方法，包括向有需要的受试者施用治疗有效量的式（I）化合物或其药学上可接受的形式。
-
公开(公告)号：US20110230440A1
公开(公告)日：2011-09-22
申请号：US13049785
申请日：2011-03-16
申请人： Julian Adams , Mark L. Behnke , Alfredo C. Castro , Catherine A. Evans , Louis Grenier , Michael J. Grogan , Tao Liu , Daniel A. Snyder , Thomas T. Tibbitts
发明人： Julian Adams , Mark L. Behnke , Alfredo C. Castro , Catherine A. Evans , Louis Grenier , Michael J. Grogan , Tao Liu , Daniel A. Snyder , Thomas T. Tibbitts
IPC分类号： A61K31/69 , C07F5/02 , A61P29/00 , A61P25/00 , A61P37/00 , A61P25/22 , A61P25/24 , A61P27/06 , A61P9/00
摘要： The present invention provide compounds, and pharmaceutical compositions thereof, encompassed by the formulae (I), (II) or (III). The present invention also provides methods for treating an FAAH mediated disease, disorder or condition by administering a therapeutically effective amount of a provided compound of the formulae (I), (II) or (III), or a pharmaceutical composition thereof, to a patient in need thereof. Additionally, the present invention provides methods for inhibiting FAAH in a patient by administering a therapeutically effective amount of a compound of the formulae (I), (II) or (III), or a pharmaceutical composition thereof, to a patient in need thereof.
-
公开(公告)号：US20110028478A1
公开(公告)日：2011-02-03
申请号：US12782650
申请日：2010-05-18
申请人： Mark L. Behnke , Alfredo C. Castro , Lawrence K. Chan , Catherine A. Evans , Louis Grenier , Michael J. Grogan , Yves Leblanc , Tao Liu , Stephane Peluso , Daniel A. Snyder , Thomas T. Tibbitts
发明人： Mark L. Behnke , Alfredo C. Castro , Lawrence K. Chan , Catherine A. Evans , Louis Grenier , Michael J. Grogan , Yves Leblanc , Tao Liu , Stephane Peluso , Daniel A. Snyder , Thomas T. Tibbitts
IPC分类号： A61K31/5377 , C07D261/04 , A61K31/42 , A61P29/00 , A61P27/06 , A61P9/10 , A61P37/00 , A61P17/00 , A61P25/28 , A61P1/08 , A61P25/30 , A61P9/12 , A61P3/04 , C07D413/12 , A61K31/4439 , A61K31/506 , A61K31/501 , C07D413/10 , A61K31/4245 , A61K31/4709
CPC分类号： A61K31/42 , A61K31/4245 , A61K31/4439 , A61K31/4709 , A61K31/501 , A61K31/506 , A61K31/5377 , C07D261/04 , C07D413/04 , C07D413/12 , C07D413/14 , C07D471/04
摘要： The present invention provides isoxazoline FAAH inhibitors of the formula (I): or pharmaceutically acceptable forms thereof, wherein each of G, Ra, Rb, Rc, and Rd are as defined herein. The present invention also provides pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable form thereof, and a pharmaceutically acceptable excipient.The present invention also provides methods for treating an FAAH-mediated condition comprising administering a therapeutically effective amount of a compound of formula (I), or pharmaceutically acceptable form thereof, to a subject in need thereof.
-
公开(公告)号：US08927551B2
公开(公告)日：2015-01-06
申请号：US12782655
申请日：2010-05-18
申请人： Mark L. Behnke , Alfredo C. Castro , Lawrence K. Chan , Catherine A. Evans , Louis Grenier , Michael J. Grogan , Yves Leblanc , Tao Liu , Stephane Peluso , Daniel A. Snyder , Thomas T. Tibbitts
发明人： Mark L. Behnke , Alfredo C. Castro , Lawrence K. Chan , Catherine A. Evans , Louis Grenier , Michael J. Grogan , Yves Leblanc , Tao Liu , Stephane Peluso , Daniel A. Snyder , Thomas T. Tibbitts
IPC分类号： A61K31/498 , C07D413/04 , A61K31/4439 , C07D401/14 , A61K31/506 , A61K31/424 , C07D401/04 , A61K31/454 , C07D413/06 , A61K31/496 , C07D403/10 , C07D401/10 , C07D417/04 , C07D417/14 , C07D413/14 , C07D261/04
CPC分类号： C07D413/04 , C07D261/04 , C07D413/14 , C07D417/04 , C07D417/14
摘要： The present invention provides isoxazoline FAAH inhibitors of the formula (I): or pharmaceutically acceptable forms thereof, wherein each of G, Ra, Rb, Rc, and Rd are as defined herein. The present invention also provides pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable form thereof, and a pharmaceutically acceptable excipient.The present invention also provides methods for treating an FAAH-mediated condition comprising administering a therapeutically effective amount of a compound of formula (I), or pharmaceutically acceptable form thereof, to a subject in need thereof.
-
-
-
-
-
-
-
-
-
搜索结果
187 条记录 (耗时 0.061 秒)
